SARS-CoV-2 N protein induces acute kidney injury in diabetic mice via the Smad3-Ripk3/MLKL necroptosis pathway

导出学术成果认领

摘要Dear Editor,Kidney is one of major organs attacked by SARS-CoV-2,resulting in acute kidney injury(AKI)in critically ill COVID-19 patients,especially in the elderly and diabetic patients with diabetic kidney disease(DKD).1,2 Among SARS-CoV-2 proteins,the N protein can be detectable in damaged tubules in CO VID-19 patients with AKI.2,3 However,the role and mechanisms of N protein-induced AKI in diabetes remain unclear.

作者 Liying Liang ^[1] Wenbiao Wang ^[2] Junzhe Chen ^[3] Wenjing Wu ^[4] Xiao-Ru Huang ^[4] Biao Wei ^[5] Yu Zhong ^[5] Ronald C.W.Ma ^[5] Xueqing Yu ^[2] Hui-Yao Lan ^[4] 学术成果认领

作者单位 Departments of Medicine & Therapeutics,Li Ka Shing Institute of Health Sciences,and Lui Che Woo Institute of Innovative Medicine,The Chinese University of Hong Kong,Hong Kong,China;Department of Clinical Pharmacy,Guangzhou Eighth People's Hospital,Guangzhou Medical University,Guangzhou,China;The Chinese University of Hong Kong-Guangdong Academy of Sciences/Guangdong Provincial People's Hospital Joint Research Laboratory on Immunological and Genetic Kidney Diseases,The Chinese University of Hong Kong,Hong Kong,China ^[1] The Chinese University of Hong Kong-Guangdong Academy of Sciences/Guangdong Provincial People's Hospital Joint Research Laboratory on Immunological and Genetic Kidney Diseases,The Chinese University of Hong Kong,Hong Kong,China;Guangdong-Hong Kong Joint Laboratory for Immunological and Genetic Kidney Disease and Medical Research Center,and Departments of Nephrology and Pathology,Guangdong Academy of Medical Science,Guangdong Provincial People's Hospital,Guangzhou,China ^[2] Departments of Medicine & Therapeutics,Li Ka Shing Institute of Health Sciences,and Lui Che Woo Institute of Innovative Medicine,The Chinese University of Hong Kong,Hong Kong,China;Department of Nephrology,The Third Affiliated hospital,Southern Medical University,Guangzhou,China ^[3] Departments of Medicine & Therapeutics,Li Ka Shing Institute of Health Sciences,and Lui Che Woo Institute of Innovative Medicine,The Chinese University of Hong Kong,Hong Kong,China;The Chinese University of Hong Kong-Guangdong Academy of Sciences/Guangdong Provincial People's Hospital Joint Research Laboratory on Immunological and Genetic Kidney Diseases,The Chinese University of Hong Kong,Hong Kong,China;Guangdong-Hong Kong Joint Laboratory for Immunological and Genetic Kidney Disease and Medical Research Center,and Departments of Nephrology and Pathology,Guangdong Academy of Medical Science,Guangdong Provincial People's Hospital,Guangzhou,China ^[4] Departments of Medicine & Therapeutics,Li Ka Shing Institute of Health Sciences,and Lui Che Woo Institute of Innovative Medicine,The Chinese University of Hong Kong,Hong Kong,China ^[5]

栏目名称 LETTERS

DOI 10.1038/s41392-023-01410-x

发布时间 2024-03-14